Papers - Tanigawara, Yusuke

A randomized phase II clinical trial of tailored CPT-11+S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy

Y. Takahashi, J. Sakamoto, T. Takeuchi, M. Mai, T. Kubota, M. Kitajima, Y. Tanigawara, Y. Komatsu, T.Toge, S. Saji

Jpn. J. Clin. Oncol. 34 ( 6 ) 342-345 2004

Research paper (scientific journal), Joint Work, Accepted

Relationship between pharmacokinetic parameters and occurrence of adverse events in clinical trials performed in Europe and United States for an angiotensin II receptor antagonist, telmisartan

S. Tatami, A. Sarashina, N. Yamamura, T. Igarashi, Y. Tanigawara

Drug. Metab. Pharmacokinet. 19 ( 1 ) 24-32 2004

Research paper (scientific journal), Joint Work, Accepted

Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method

S. Tatami, N. Yamamura, A. Sarashina, CL Yong, T. Igarashi, Y. Tanigawara

Drug. Metab. Pharmacokinet. 19 ( 1 ) 15-23 2004

Research paper (scientific journal), Joint Work, Accepted

Pharmacokinetics and pharmacodynamics of meropenem in patients with severe infections（PDFなし）

''MORITA KUNIHIKO, SHIMADA MASAHIKO, KOBAYASHI YOSHIO, TANIGAWARA YUSUKE''

Therapeutic drug monitoring 25 ( 4 ) 527 2003.08

Research paper (conference, symposium, etc.), Joint Work

Dosage Planning Software for Valproic Acid (Valerin) Using Microsoft Excel

''KASAI HIDEFUMI, TERAUCHI YOSHIAKI, FUJII TOSHIHIKO, TANIGAWARA YUSUKE''

The Japanese Journal of Therapeutic Drug Monitoring 20 ( 3 ) 257-262 2003.07

Research paper (scientific journal), Joint Work, Accepted

Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors

Yamamoto Noboru, Tamura Tomohide, Kamiya Yoshikazu, Ono Hiroyuki, Kondoh Hitoshi, Shirao Kuniaki, Matsumura Yasuhiro, Tanigawara Yusuke, Shimada Yasuhiro

Japanese Journal of Clinical Oncology 33 ( 6 ) 302 - 308 2003.06

ISSN  0368-2811

　View Summary

<p>Background: KRN5500, a novel spicamycin derivative, shows an inhibitory effect on protein synthesis. This phase I study was aimed at investigating the toxicity, maximum tolerated dose (MTD) and pharmacokinetics of this compound. Patients and methods: Patients with solid tumors not amenable to standard forms of treatment were eligible. KRN5500 was administered as a 2 h intravenous infusion every 4 weeks at doses of 3, 6, 10, 15 and 21 mg/m². Pharmacokinetic evaluation was performed at the first cycle. Results: Eighteen patients with advanced solid tumors were enrolled. A total of 26 cycles of KRN5500 were administered. The major toxicities were nausea, vomiting, diarrhea, fatigue and a mild reversible prolongation of prothrombin time. Grade 4 pulmonary toxicity (interstitial pneumonitis) was observed in one patient at a dose level of 15 mg/m². Severe fatigue was observed in one patient at a dose level of 21 mg/m² and the duration of fatigue tended to increase with the dose of KRN5500. Nausea and vomiting were frequently observed and became prolonged with increasing dose of KRN5500. These toxicity profiles were identified as unacceptable and further dose escalation above 21 mg/m² was withheld. The MTD was therefore determined as 21 mg/m². The peak plasma concentration and the area under the concentration-time curve of KRN5500 increased proportionally to the dose, suggesting linear pharmacokinetics. No objective antitumor response was observed. Conclusion: KRN5500, a structurally novel protein synthesis inhibitor, warrants further investigation to overcome these toxicity profiles and improve its efficacy. © 2003 Foundation for Promotion of Cancer Research.</p>

• Access to Document (DOI)

Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in heealthy volunteers and hypertensive patients

S. Tatami, A. Sarashina, N. Yamamura, T. Igarashi, Y. Tanigawara

Drug Metabol. Pharmacokin. 18 ( 3 ) 203-211 2003

Research paper (scientific journal), Joint Work, Accepted

Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients

E. Comets, K. Ikeda, P. Hoff, P. Fumoleau, J. Wanders, Y. Tanigawara

J. Pharmacokin. Pharmacodyn. 30 ( 4 ) 257-283 2003

Research paper (scientific journal), Joint Work, Accepted

本邦における抗MRSA薬arbekacinを中心とした使用実態

清水喜八郎，相川直樹，谷川原祐介，賀来満夫，今栄雅文，西澤宣典，中村　洋

日本化学療法学会雑誌 51 ( 11 ) 717-730 2003

Research paper (scientific journal), Joint Work, Accepted

小児科領域感染症におけるmeropenemの臨床的検討

豊永義清，砂川慶介，本廣　孝，岩井直一，谷川原祐介，遠藤廣子，佐藤吉壮，黒木春郎，皆川真規，石和田稔彦，田島　剛，岩田　敏，長　秀男，砂押　渉，加藤達夫，番場正博，若宮英司，杉田久美子，山崎　剛，川村尚久，春田恒和，古川正強，岡田隆滋，藤本　保，石原高信，安藤昭和，津村直幹

日本化学療法学会雑誌 51 ( 12 ) 762-781 2003

Research paper (scientific journal), Joint Work, Accepted

MDR1-Mediated interaction of digoxin with antiarrhythmic or antianginal drugs

Kakumoto Mikio, Takara Kohji, Sakaeda Toshiyuki, Tanigawara Yusuke, Kita Tomoko, Okumura Katsuhiko

Biological ＆ pharmaceutical bulletin 25 ( 12 ) 1604-1607 2002.12

Research paper (scientific journal), Joint Work

成人生体肝移植におけるネオーラル投与の実際

'Kawachi Shigeyuki, Shimazu Motohide, Wakabayashi Gou, Tanabe Minoru, Hoshino Ken, Nagasaki Kazuhito, Shibutani Shintarou, Morikawa Yasuhide, Morita Kunihiko, Tanigawara Yuusuke, Kitajima Masaki'

今日の移植 15 ( 6 ) 591-593 2002.11

Research paper (scientific journal), Joint Work

がん性疼痛における麻薬製剤の特徴と服薬指導（PDFなし）

'Nashimoto Kyouko, Maeda Uki, Tanigawara Yuusuke, Takeda Junzou'

ペインクリニック 23 ( 9 ) 1214-1221 2002.09

Research paper (scientific journal), Joint Work

生体肝移植例におけるネオーラルの薬物動態モニタリング（PDFなし）

'Kawachi Shigeyuki, Shimazu Motohide, Wakabayashi Gou, Tanabe Minoru, Hoshino Ken, Nagasaki Kazuhito, Shibutani Shintarou, Morikawa Yasuhide, Morita Kunihiko, Tanigawara Yuusuke, Kitajima Masaki'

今日の移植 15 ( 5 ) 523-525 2002.09

Research paper (scientific journal), Joint Work

Thalidomide for the treatment of refractory multiple myeloma : association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome

Kakimoto Tsunayuki, Hattori Yutaka, Okamoto Shinichiro, Sato Norihide, Kamata Tamihiro, Yamaguchi Masaya, Morita Kunihiko, Yamada Taketo, Takayama Nobuyuki, Uchida Hideo, Shimada Naoki, Tanigawara Yusuke, Ikeda Yasuo

Japanese journal of cancer research 93 ( 9 ) 1029-1036 2002.09

Research paper (scientific journal), Joint Work

N-Acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events

Tanigawara Yusuke, Kita Tomoko, Aoyama Nobuo, Gobara Manabu, Komada Fusao, Sakai Toshiyuki, Kasuga Masato, Hatanaka Hisakatsu, Sakaeda Toshiyuki, Okumura Katsuhiko,

Biological & pharmaceutical bulletin 25 ( 8 ) 1058-1062 2002.08

Research paper (scientific journal), Joint Work

Interaction of digoxin with antihypertensive drugs via MDR1

Takara Kohji, Kakumoto Mikio, Tanigawara Yusuke, Funakoshi Junko, Sakaeda Toshiyuki, Okumura Katsuhiko

Life Sciences 70 ( 13 ) 1491 - 1500 2002.02

ISSN  0024-3205

　View Summary

<p>The multidrug transporter MDR1 (P-glycoprotein)-mediated interaction between digoxin and 29 antihypertensive drugs of various types was examined by using the MDR1 overexpressing LLC-GA5-COL150 cells, which were established by transfecting MDR1 cDNA into porcine kidney epithelial LLC-PK₁ cells. These cells construct monolayers with tight junctions, and enable the evaluation of transcellular transport. The MDR1 was highly expressed on the apical membrane (urine side). The basal-to-apical and apical-to-basal transcellular transport of [³H]digoxin in LLC-GA5-COL150 cells was time- and temperature-dependent. The basal-to-apical transport of [³H]digoxin was markedly increased, whereas the apical-to-basal transport was decreased in LLC-GA5-COL150 cells, compared with the host LLC-PK₁ cells, suggesting that [³H]digoxin was a substrate for MDR1. Most of the Ca²⁺ channel blockers used here markedly inhibited basal-to-apical transport and increased apical-to-basal transport. Exceptions were diltiazem, nifedipine and nitrendipine, which hardly showed inhibitory effects on transcellular transport of [³H]digoxin. α-Blocker doxazosin and β-blocker carvedilol also inhibited transcellular transport of [³H]digoxin, but none of the angiotensin converting enzyme inhibitors and AT₁ angiotensin II receptor antagonists used here were active. These observations will promote understanding of the digoxin-drug interactions resulting from their actions on MDR1, and which may aid in avoiding these unexpected effects of digoxin. © 2002 Elsevier Science Inc. All rights reserved.</p>

• Access to Document (DOI)

Digoxinと高血圧治療薬との相互作用

Oomoto Nobuko，Tanigawara Yuusuke，Kakumoto Mikio，Funakoshi Junko，Takara Kouji，Nakamura Tsutomu，Sakaeda Toshiyuki，Hirai Midori，Okumura Katsuhiko

TDM研究 19 ( 1 ) 58-64 2002.01

Research paper (scientific journal), Joint Work

Effects of 12 Ca²⁺ antagonists on multidrug resistance, MDR1-mediated transport and MDR1 mRNA expression

Takara Kohji, Sakaeda Toshiyuki, Tanigawara Yusuke, Nishiguchi Kohshi, Ohmoto Nobuko, Horinouchi Masanori, Komada Fusao, Ohnishi Noriaki, Yokoyama Teruyoshi, Okumura Katsuhiko

European Journal of Pharmaceutical Sciences 16 ( 3 ) 159 - 165 2002

ISSN  0928-0987

　View Summary

<p>The effects of 12 Ca²⁺ antagonists on MDR1 were examined by two independent models: the inhibitory effect on MDR1-mediated transport of [³H]digoxin using MDR1-overexpressing LLC-GA5-COL150 cell monolayers and the reversal effect on cytotoxicity of vinblastine or paclitaxel using MDR1-overexpressing Hvr100-6 cells. The inhibitory effects on [³H]digoxin transport were assessed as the 50% inhibitory concentration during 4 h exposure, and the values were the lowest for nicardipine (4.54 μM), manidipine (4.65 μM) and benidipine (4.96 μM), followed by bepridil (10.6 μM), barnidipine (12.6 μM), efonidipine (13.0 μM), verapamil (13.2 μM) and nilvadipine (18.0 μM). The reversal effect on cytotoxicity was assessed by the 50% growth inhibitory concentration after 3 days exposure, and the resistance to vinblastine or paclitaxel in Hvr100-6 cells was reversed by manidipine, verapamil, benidipine, barnidipine, and nicardipine, in that order. Bepridil, barnidipine, efonidipine, verapamil and nilvadipine showed similar inhibitory effects on [³H]digoxin transport, but barnidipine and verapamil showed a stronger effect in reversal of cytotoxicity. Real-time quantitative RT-PCR assay indicated a decrease in MDR1 mRNA expression by barnidipine and verapamil. It is concluded that Ca²⁺ antagonists cannot only be direct inhibitors of MDR1 but that some may at the same time act as inhibitors of expression of MDR1 via down-regulation of MDR1 mRNA. © 2002 Elsevier Science B.V. All rights reserved.</p>

• Access to Document (DOI)

高齢者におけるfaropenem sodiumの体内動態ならびに安全性の検討

柴　孝也，加治木　章，原田泰子，原田　進，高本　正祇，宮崎三弘，小山　優，山田陽介，千田　守，山本俊信，鈴木幹三，谷川原祐介

日本化学療法学会雑誌 50 ( 10 ) 640-645 2002

Research paper (scientific journal), Joint Work, Accepted